Attorneys general of New York, other states urge FDA to expand access to abortion pill

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ

The attorneys general of New York, California and Massachusetts have called on the federal Food and Drug Administration (FDA) to expand access to the abortion pill mifepristone and remove "outdated restrictions."

The pill mifepristone, approved in 2000 for use with misoprostol, is used to perform a medical abortion in the first 10 weeks of pregnancy. Medical abortions now account for more than half of all terminations of pregnancy in the United States, despite 28 states restricting access to the early abortion drug.

The attorneys general of New York, Massachusetts and California have called on the FDA to expand federal access to the pill. In a petition filed with the Food and Drug Administration, they challenged three FDA requirements for mifepristone. Among other things, the prosecutors challenged the requirement for doctors who prescribe the drug to register on national and local abortion providers lists. They also support eliminating the requirement for patients to provide written notice of their intention to terminate a pregnancy and for pharmacies to keep mandatory records of mifepristone sales.

New York Attorney General Letitia James called the restrictions “medically unnecessary” and impeding access to “essential health care.”

It’s not yet clear how federal authorities will respond. President Donald Trump distanced himself from abortion during his 2024 campaign, although he largely supported abortion opponents in his previous term. In 2024, Trump said he had no plans to restrict access to mifepristone.

Ed. JŁ